Loading
PD-L1 Inhibitor Rechallenge / PD-1 Inhibitor Rechallenge / Rechallenge · Observational Study
ClinicalTrials.gov · August 20, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a planned multicenter observational study registered on ClinicalTrials.gov that will compare the recurrence rate of checkpoint inhibitor pneumonitis (CIP) in lung cancer patients who are rechallenged with PD-L1 inhibitors, PD-1 inhibitors, or no immune checkpoint inhibitor after prior CIP-related toxicity. No results have been reported in this registry record; the study is currently recruiting.
Observational. Lung Cancer, Rechallenge, Checkpoint Inhibitor Pneumonitis; age from 18 Years. Intervention: PD-L1 Inhibitor Rechallenge Cohort; PD-1 Inhibitor Rechallenge Cohort; No Immune Checkpoint Inhibitor Rechallenge Cohort. Compared with: No immune checkpoint inhibitor rechallenge. n = 150. 5 sites: China.
This is a planned multicenter observational study registered on ClinicalTrials.gov that will compare the recurrence rate of checkpoint inhibitor pneumonitis (CIP) in lung cancer patients who are rechallenged with PD-L1 inhibitors, PD-1 inhibitors, or no immune checkpoint inhibitor after prior CIP-related toxicity. No results have been reported in this registry record; the study is currently recruiting.
Secondary outcomes (immune-related adverse events, progression-free survival, overall survival, objective response rate, disease control rate) are planned but not yet reported.
The source did not state who this applies to in practice.
This is an observational registry study in recruitment with no reported results; it describes a planned comparison of checkpoint inhibitor rechallenge strategies in lung cancer patients with prior pneumonitis, addressing an important safety question but delivering no outcome data yet.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07775820). This is a study registration, not published results. Lead sponsor: Nanfang Hospital, Southern Medical University. Recruitment status: RECRUITING. Study type: OBSERVATIONAL. Enrollment: 150 participants (ESTIMATED). Conditions: Lung Cancer, Rechallenge, Checkpoint Inhibitor Pneumonitis. Interventions: DRUG: PD-L1 Inhibitor Rechallenge; DRUG: PD-1 Inhibitor Rechallenge; DRUG: No Immune Checkpoint Inhibitor Rechallenge. Primary outcome measures: Recurrence Rate of Checkpoint Inhibitor Pneumonitis After Immune Checkpoint Inhibitor Rechallenge , From the date of immune checkpoint inhibitor rechallenge to the first documented CIP recurrence, death, or study completion, whichever occurs first, assessed for up to 5 years.. Brief summary: This multicenter observational study will evaluate the safety and effectiveness of immune checkpoint inhibitor rechallenge in adults with lung cancer who developed checkpoint inhibitor pneumonitis. The study will use both retrospective medical records and prospective follow-up data. Participants will not be assigned to any treatment by the study protocol. All treatment decisions will be made by the treating physicians as part of routine clinical care. Participants will be classified into three groups according to their subsequent treatment: rechallenge with a PD-L1 inhibitor, rechallenge with a PD-1 inhibitor, or no immune checkpoint inhibitor rechallenge. The primary outcome is the recurrence of checkpoint inhibitor pneumonitis after rechallenge. Secondary outcomes include immune-related adverse events, progression-free survival, overall survival, objective response rate, and disease control rate at 24 weeks. Approximately 150 participants will be included across multiple study centers in China.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.